Symbiotec Pharmalab lists today after Rs 112.50 crore debt-use plan
In short
Symbiotec Pharmalab is set to list today after its IPO. Market summaries say the stock could open about 19% to 22% above its issue price of ₹988, with a grey market premium of ₹185 and an estimated listing price near ₹1,173.
The company also planned to use Rs 112.50 crore to repay some borrowings. The real listing price is still not known.
What the reporting says
Symbiotec Pharmalab is preparing for its IPO listing today, with publisher summaries saying the stock may debut at a premium or discount. The reports cite grey market premium signals implying about a 19% to 22% rise and an estimated listing price near ₹1,173 versus the IPO price of ₹988. The issue also planned to use Rs 112.50 crore for prepayment or repayment of select borrowings; the actual listing outcome is still unknown.
Why it matters
Symbiotec Pharmalab is listed in publisher summaries as having an IPO listing today, with grey market signals pointing to a possible premium on debut. The issue also included a planned use of Rs 112.50 crore for prepayment or repayment of select outstanding borrowings, which could ease debt pressure. The market impact depends on the actual listing price, which is not stated in the available reporting.